Case number IPR2017-01094
Celltrion Inc. et al. v. Biogen, Inc. > Documents
| Date Field | Doc. No. | Party | Description |
|---|---|---|---|
| Jan 12, 2018 | 17 | Notice of Refund Download | |
| Jan 5, 2018 | 16 | Petitioner's Request for Refund of Post-Institution Fee Download | |
| Jan 2, 2018 | 15 | Decision - Denying Petitioner's Request for Rehearing Download | |
| Dec 27, 2017 | 14 | Patent Owner's Updated Mandatory Notice Download | |
| Nov 1, 2017 | 13 | Petitioner's Request for Rehearing Pursuant to 37 C.F.R. Section 42.71(c) and (d) Download | |
| Oct 2, 2017 | 12 | Trial Instituted Document Download | |
| Jul 5, 2017 | 11 | Patent Owner's Exhibit List Download | |
| Jul 5, 2017 | 2007 | Ex 2007 Bio Report Download | |
| Jul 5, 2017 | 2009 | Ex 2009 Meyer 1997 Download | |
| Jul 5, 2017 | 2001 | Ex 2001 Al Ismail Download | |
| Jul 5, 2017 | 2006 | Ex 2006 Martelli Download | |
| Jul 5, 2017 | 2008 | Ex 2008 '172 Patent Download | |
| Jul 5, 2017 | 10 | Patent Owner's Preliminary Response Download | |
| Jul 5, 2017 | 2003 | Ex 2003 Hiddemann 1996 Download | |
| Jul 5, 2017 | 2002 | Ex 2002 Hiddemann 1995 Download | |
| May 15, 2017 | 9 | NOTICE OF ACCEPTING CORRECTED PETITION Download | |
| Apr 7, 2017 | 8 | Notice of Corrected Exhibit Download | |
| Apr 7, 2017 | 1026 | (Corrected) Leget, G.A. et al., Use of rituximab, the new FDA-approved antibody, Curr. Opin. Oncol., 10(6):548-551 (Nov. 1998) Download | |
| Apr 5, 2017 | 6 | Power of Attorney Download | |
| Apr 5, 2017 | 5 | Notice of Defective Petition Download | |
| Apr 5, 2017 | 7 | Mandatory Notice Download | |
| Mar 17, 2017 | 3 | Certificate of Service re Corrected Exhibits Download | |
| Mar 17, 2017 | 4 | Petitioner's Updated Mandatory Notice re Lead Backup Counsel Download | |
| Mar 17, 2017 | 1004 | Longo Declaration (Corrected) Download | |
| Mar 17, 2017 | 1003 | Lossos Declaration (Corrected) Download | |
| Mar 15, 2017 | 1005 | Link, et al., Phase II Pilot Study of the Safety and Efficacy of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Intermediate- or High-Grade NHL, Program/Proceedings Am. Soc. Clin. Oncol., 17:3a (Abstract 7), 1998 Download | |
| Mar 15, 2017 | 1009 | Sonneveld, et al., Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advance Diffuse Non-Hodgkin's Lymphoma Using CHOP Versus CNOP Chemotherapy, J. Clin. Oncol., 13(10):2530-39 (Oct. 1995) Download | |
| Mar 15, 2017 | 1001 | U.S. Patent No. 8,557,244 Download | |
| Mar 15, 2017 | 1020 | Stashenko, et al., Characterization of a Human B Lymphocyte-Specific Anigen, J. Immunol., 125(4):1678-1685 (Oct. 1980) Download | |
| Mar 15, 2017 | 1003 | Expert Declaration of Dr. Izidore Lossos Download | |
| Mar 15, 2017 | 2 | Petitioner's Petition for Inter Partes Review of U.S. Patent No. 8,557,244 Download | |
| Mar 15, 2017 | 1024 | Vose et al., Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients with Previously Untreated, Aggressive Non-Hodgkin's Lymphoma, J. Clin. Oncol., 19(2):389-397 (Jan. 15, 2001) Download | |
| Mar 15, 2017 | 1025 | The Non-Hodgkin's Lumphoma Pathologic Classification Project, National Cancer Institute Sponspored Study of Classifications of Non-Hodgkin's Lymphomas: etc., Cancer, 49(10):2112-2135 (May 15, 1982) Download | |
| Mar 15, 2017 | 1044 | Armitage, Treatment of Non-Hodgkin's Lymphoma, New Engl. J. Med., 328(14):1023-1030 (Apr. 8, 1993) Download | |
| Mar 15, 2017 | 1031 | Reff, et al., Depletion of B Cells in Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20, Blood, 83(2):435-445 (Jan. 15, 1994) Download | |
| Mar 15, 2017 | 1019 | Fisher, et al., Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma, New. Engl. J. Med., 328(14):1002-1006 (Apr. 8, 1993) Download | |
| Mar 15, 2017 | 1038 | Shipp, et al., Section 3: Non-Hodgkin's Lymphomas, in Cancer: Principles & Practice on Oncology, 5th edition, 2165-2223 (DeVita, V.T. et al., eds. 1997) Download | |
| Mar 15, 2017 | 1018 | Gordon, et al., Comparison fo a Second-Generation Combination Chemotherapeutic Regimen (m-BADOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's Lymphoma, New Engl. J. Med., 327(19):1342-1349 (Nov. 5, 1992) Download | |
| Mar 15, 2017 | 1006 | McNeil, Non-Hodgkin's Lymphoma Trials in Elderly Look Beyond CHOP, J. Nat'l Cancer Inst., 90(4):266-67 (Feb. 18 1998) Download | |
| Mar 15, 2017 | 1013 | Ford, Rituxan (Rituximab), The CAL GAB, Quarterly Newsletter of the Cancer and Leukemia Group B, 7(1):4-5 (Spring 1998) Download | |
| Mar 15, 2017 | 1034 | Anderson, et al., Targeted anti-cancer therapy using rituximab, a chemaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-Cell lymphoma, Biochem. Soc. T., 25(2):705-708 (May 1997) Download | |
| Mar 15, 2017 | 1004 | Expert Declaration of Dr. Walter Longo Download | |
| Mar 15, 2017 | 1039 | FDA FOIA Response Letter (August 26, 2016) Download | |
| Mar 15, 2017 | 1008 | Rituxan (Rituximab) Label (Nov. 1997) Download | |
| Mar 15, 2017 | 1003 | Expert Declaration of Dr. Izidore Lossos Download | |
| Mar 15, 2017 | 1007 | Eastern Coperative Oncology Group E4494 Patient Consent Form (1997) Download | |
| Mar 15, 2017 | 1052 | DeVita, V.T. et al., Chapter 44: Hodgkin's Disease and the Non-Hodgkin's Lymphomas, in Cancer: Principles & Practice of Oncology, Second Edition (Devita, Jr. et al., eds., 1985) Download | |
| Mar 15, 2017 | 1027 | Harris, et al., A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group, Blood, 84(5):1361-1392 (Sept. 1 1994) Download | |
| Mar 15, 2017 | 1011 | Davis, et al., Rituximab: First Report of a Phase II (PII) Trial in NHL Patients (PTS) with Bulky Disease, Blood, 92(10) Suppl. 1):414a (Abstract 1711) (Nov. 15, 1998) Download | |
| Mar 15, 2017 | 1026 | Leget, et al., Use of rituximab, the new FDA-approved antibody, Curr. Opin. Oncol., 10(6):548-551 (Nov. 1998) Download | |
| Mar 15, 2017 | 1023 | Foon, et al., Chapter 111: Lymphomas in Williams Hematology, Fifth Edition, 1076-1096 (Beutler, E. et al. eds., 1995) Download | |
| Mar 15, 2017 | 1002 | Excerpts from the certified filed history of the '244 patent Download | |
| Mar 15, 2017 | 1046 | Eastern Cooperative Oncology Group E4494 Protocol (1997) Download | |
| Mar 15, 2017 | 1021 | Anderson, et al., Expression of Human B Cell-Associated Antigens on Leukemias and Lymphomas: A Model of Human B Cell Differentiation, Blood, 63(6):1524-1433 (June 1984) Download | |
| Mar 15, 2017 | 1043 | Armitage, et al., New Approach to Classifying Non-Hodgkin's Lymphomas: Clinical Features of the Major Histologic Subtypes, J. Clin. Oncol., 16(8):2780-2795 (aUG. 1998) Download | |
| Mar 15, 2017 | 1028 | Ford, et al., Immunotherapeutic Approaches to Treatment of B-Cell Neoplasms: Focus on Unconjugated Antibodies, Highlights in Oncology Practice, 16(2):40-50 (1998) Download | |
| Mar 15, 2017 | 1016 | Czuczman, et al., Chemoimmunotherapy of Low-Grade Lymphoma with the Anti-CD20 Anitbody IDEC-C2B8 in Combination with CHOP Chemotherapy, Cancer Invest., 14(Supp. 1):59-61 (Abstract 53) (1996) Download | |
| Mar 15, 2017 | 1049 | Eastern Cooperative Oncology Group Protocols Active as of May 19, 1998 Download | |
| Mar 15, 2017 | 1004 | Expert Declaration of Dr. Walter Longo Download | |
| Mar 15, 2017 | 1012 | Davis, et al., Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab, J. Clin, Oncol., 17(6):1851-57 (June 1999) Download | |
| Mar 15, 2017 | 1026 | Leget, et al., Use of rituximab, the new FDA-approved antibody, Curr. Opin. Oncol., 10(6):548-551 (Nov. 1998) Download | |
| Mar 15, 2017 | 1029 | IDEC Pharmaceuticals Corporation, Form 10-K/A for the Fiscal Year ended December 31, 1997 filed with the U.S. Securities and Exchange Commission Download | |
| Mar 15, 2017 | 1 | Petitioner's Power of Attorney Download | |
| Mar 15, 2017 | 1045 | Smith, Rituximab (monoclonal anti-CD20 antibody): mechanism of action and resistance, Oncogene, 2(47):7359-7368 (Oct. 20, 2003) Download | |
| Mar 15, 2017 | 1037 | Coiffier, et al., CHOP Chemotherapy Plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, N. Engl. J. Med., 346(4):235-242 (Jan 24, 2002) Download | |
| Mar 15, 2017 | 1015 | Coiffier, et al., Rituximab (Anti-CD20) Monoclonal Antibody) for the Treatment of Patients with Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study, Blood, 92(6):1927-1932 (Sept. 15, 1998) Download | |
| Mar 15, 2017 | 1010 | Public Hearing Transcript, Biological Response Modifiers Advisory Committee, Center for Biological Evaluation and Research, Food and Drug Administration, Nineteenth Meeting (July 25, 1997) Download | |
| Mar 15, 2017 | 1014 | Coiffier, et al., A multicenter, randomized phase II study of rituximab (chimeric anti-CD20 mAb) at two dosages in patients with relapsed or refractor intermediate or high-grade NHL (IHG-NHL) et al., Blood, 90(10):510a (Abstract 2271) (Nov. 15, 1997) Download | |
| Mar 15, 2017 | 1051 | Eastern Cooperative Oncology GroupE4494 On Study Dates Download |
